The firm said it upped its numbers on the company, which provides health care products and services to office-based practitioners, based on the company's improved outlook.
"Our new price target implies shares can trade at roughly 22-23x our full year 2015 EPS estimate of $5.95. The higher-than-historic-average target multiple reflects a higher market multiple as well as the potential outlook for improvements in key end markets," the firm said.
Additionally, Henry Schein reported its 2014 third quarter earnings results on Thursday, and posted a net income of $114.8 million, or $1.34 per diluted share, compared to $107.4 million, or $1.23 per diluted share for the year ago quarter.
Net sales for the most recent quarter grew by 11.7% to $2.6 billion over the 2013 third quarter.
Separately, TheStreet Ratings team rates SCHEIN (HENRY) INC as a Buy with a ratings score of A. TheStreet Ratings Team has this to say about their recommendation:
"We rate SCHEIN (HENRY) INC (HSIC) a BUY. This is based on the convergence of positive investment measures, which should help this stock outperform the majority of stocks that we rate. The company's strengths can be seen in multiple areas, such as its growth in earnings per share, increase in net income, revenue growth, notable return on equity and increase in stock price during the past year. We feel these strengths outweigh the fact that the company shows weak operating cash flow."